24 related articles for article (PubMed ID: 38666722)
1. Chemical Complementarity of Tumor Resident, Adaptive Immune Receptor CDR3s and Previously Defined Hepatitis C Virus Epitopes Correlates with Improved Outcomes in Hepatocellular Carcinoma.
Song JJ; Chobrutskiy A; Chobrutskiy BI; Cios KJ; Huda TI; Eakins RA; Diaz MJ; Blanck G
Viral Immunol; 2023 Dec; 36(10):669-677. PubMed ID: 38052065
[TBL] [Abstract][Full Text] [Related]
2. High-throughput, sliding-window algorithm for assessing chemical complementarity between immune receptor CDR3 domains and cancer mutant peptides: TRG-PIK3CA interactions and breast cancer.
Chobrutskiy BI; Chobrutskiy A; Zaman S; Yeagley M; Huda TI; Blanck G
Mol Immunol; 2021 Jul; 135():247-253. PubMed ID: 33933816
[TBL] [Abstract][Full Text] [Related]
3. TRB CDR3 chemical complementarity with HBV epitopes correlates with increased hepatocellular carcinoma, disease-free survival.
Song JJ; Chobrutskiy A; Chobrutskiy BI; Cios KJ; Huda TI; Eakins RA; Diaz MJ; Blanck G
J Med Virol; 2023 Aug; 95(8):e29043. PubMed ID: 37621059
[TBL] [Abstract][Full Text] [Related]
4. An immunoinformatics assessment of the cancer testis antigen, DDX53, as a potential early esophageal cancer antigen.
Cheng P; Cios KJ; Varkhedi M; Barker VR; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
Oncoscience; 2023; 10():59-66. PubMed ID: 37953875
[TBL] [Abstract][Full Text] [Related]
5. Chemical complementarity between immune receptor CDR3s and candidate cancer antigens correlating with reduced survival: evidence for outcome mitigation with corticosteroid treatments.
Patel AR; Patel DN; Tu YN; Yeagley M; Chobrutskiy A; Chobrutskiy BI; Blanck G
J Biomol Struct Dyn; 2023 Jul; 41(10):4632-4640. PubMed ID: 35538689
[TBL] [Abstract][Full Text] [Related]
6. Immune repertoire: A potential biomarker and therapeutic for hepatocellular carcinoma.
Han Y; Li H; Guan Y; Huang J
Cancer Lett; 2016 Sep; 379(2):206-12. PubMed ID: 26188280
[TBL] [Abstract][Full Text] [Related]
7. Celiac disease: risk assessment, diagnosis, and monitoring.
Setty M; Hormaza L; Guandalini S
Mol Diagn Ther; 2008; 12(5):289-98. PubMed ID: 18803427
[TBL] [Abstract][Full Text] [Related]
8. Gliadin as a stimulator of innate responses in celiac disease.
Londei M; Ciacci C; Ricciardelli I; Vacca L; Quaratino S; Maiuri L
Mol Immunol; 2005 May; 42(8):913-8. PubMed ID: 15829281
[TBL] [Abstract][Full Text] [Related]
9. The gluten-host interaction.
Tighe MR; Ciclitira PJ
Baillieres Clin Gastroenterol; 1995 Jun; 9(2):211-30. PubMed ID: 7549025
[TBL] [Abstract][Full Text] [Related]
10. [The identification of the immunodominant gliadin epitope].
Sela B
Harefuah; 2003 Jul; 142(7):554-7, 564. PubMed ID: 12908394
[TBL] [Abstract][Full Text] [Related]
11. High-throughput quantitative assessments of the chemical complementarity of celiac disease related IGH CDR3s and a gliadin epitope.
Jain R; Bressler M; Chobrutskiy A; Chobrutskiy BI; Blanck G
Int Immunol; 2024 Apr; ():. PubMed ID: 38666722
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
